HIVAIDS patients display lower relative bioavailability of efavirenz than healthy subjects

Clinical Pharmacokinetics

Volumn 50, Issue 8, 2011, Pages 531-540

  Mukonzo, Jackson K ^a,b   Nanzigu, Sarah ^a,b   Reki, Dinko ^c   Waako, Paul ^b   Rshammar, Daniel ^d   Ashton, Michael ^c   Ogwal Okeng, Jasper ^b   Gustafsson, Lars L ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Acquired immunodeficiency syndrome; Antiretrovirals; Bioavailability; Efavirenz; HIV 1 infections; Pharmacodynamic modelling; Population pharmacokinetics

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; COTRIMOXAZOLE; CREATININE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; UREA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; UGANDA; UREA BLOOD LEVEL; ADOLESCENT; BIOAVAILABILITY; BIOLOGICAL MODEL; CLINICAL TRIAL; HALF LIFE TIME; MIDDLE AGED; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION; SEX DIFFERENCE; TISSUE DISTRIBUTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BIOLOGICAL AVAILABILITY; BODY WEIGHT; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENETICS; SEX FACTORS; TISSUE DISTRIBUTION; UGANDA; YOUNG ADULT;

EID: 79960187079     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11592660-000000000-00000     Document Type: Article

References (31)

1. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expres- sion of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15. (Pubitemid 23317282)
2. Chow HH, Tang Y, Li P, et al. The effect of chronic retrovirus infection and immune dysfunction on the P-450-mediated activation of acetaminophen in mouse liver microsomes. Biopharm Drug Dispos 1998; 19: 9-15. (Pubitemid 28064486)
3. Welage LS, Carver PL, Revankar S, et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1431-8. (Pubitemid 26066634)
4. Sadler BM, Gillotin C, Lou Y, et al. In vivo effect of alpha(1)-acid glycopro- tein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45: 852-6. (Pubitemid 32182036)
5. Laine L, Garcia F, McGilligan K, et al. Protein-losing enteropathy and hypoalbuminemia in AIDS. AIDS 1993; 7: 837-40. (Pubitemid 23212450)
6. Sabin CA, Griffioen A, Yee TT, et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet 2002; 360: 1546-51. (Pubitemid 35356369)
7. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1: 23-30.
8. Cummins AG, LaBrooy JT, Stanley DP, et al. Quantitative histological study of enteropathy associated with HIV infection. Gut 1990; 31: 317-21. (Pubitemid 20093670)
9. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3: 296-305. (Pubitemid 351521014)
10. Dickinson L, Boffito M, Back D, et al. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother 2009; 63: 1233-43.
11. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalystofefavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300. (Pubitemid 36734384)
12. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61: 148-54. (Pubitemid 43382608)
13. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007; 8: 547-58. (Pubitemid 46947859)
14. Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68: 690-9.
15. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long- term responses to antiretroviral regimens containing efavirenz and/or nelfi-navir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005; 192: 1931-42. (Pubitemid 41681891)
16. Beal SL, Boeckmann AJ, Shiner LB, editors. NONMEM user's guides. Ellicot City (MD): Icon Development Solutions, 1986-2006.
17. Wilkins JJ. NONMEMory: a run management tool for NONMEM. Comput Methods Programs Biomed 2005; 78: 259-67. (Pubitemid 40719673)
18. Jonsson EN, Karlsson MO. Xpose: an S-Plus based population pharmacoki- netic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64. (Pubitemid 29049052)
19. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57. (Pubitemid 41196689)
20. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32. (Pubitemid 351738156)
21. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit com- partment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26. (Pubitemid 47477040)
22. Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008; 52: 2138-48. (Pubitemid 351758551)
23. Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 471-3.
24. Lake-Bakaar G, Elsakr M, Hagag N, et al. Changes in parietal cell structure and function in HIV disease. Dig Dis Sci 1996; 41: 1398-408. (Pubitemid 26245921)
25. Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993; 13: 289-301. (Pubitemid 23282025)
26. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-45. (Pubitemid 34804248)
27. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18: 2391-400. (Pubitemid 40065906)
28. Elens L, Vandercam B, Yombi JC, et al. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010; 11: 1223-34.
29. Sankatsing SU, Beijnen JH, Schinkel AH, et al. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48: 1073-81. (Pubitemid 38405457)
30. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levelsin human hepatocytes. Drug Metab Dispos 2007; 35: 1687-93. (Pubitemid 47296065)
31. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88: 676-84